Earnings ·
NovaBridge Biosciences reported unaudited financial results for the six months ended June 30, 2026, posting a net loss…
IMABNovaBridge Biosciences
NovaBridge Biosciences reported unaudited financial results for the six months ended June 30, 2026, posting a net loss of $37.9 million compared to $8.7 million in the prior year period. Research and development expenses rose to $14.3 million from $4.1 million due to clinical development activities for givastomig, while administrative expenses increased to $26.4 million from $8.3 million, driven by higher share-based compensation and a one-time write-off of deferred offering costs related to a proposed HKEx dual primary listing. The company maintained a strong balance sheet with $215.9 million in cash, equivalents, short-term investments, and equity investments at fair value as of June 30, 2026. During the period, NovaBridge appointed Srishti Gupta as Chief Executive Officer and Mark Hagler as Chief Commercial Officer to strengthen leadership and governance. Pipeline updates included givastomig receiving FDA Fast Track Designation for HER2-negative gastroesophageal adenocarcinoma and preparations to initiate a Phase 3 registrational study by year-end 2026, alongside plans to begin a Phase 2b program for VIS-101 in the second half of 2026. NovaBridge Biosciences is a global biotechnology company advancing therapeutic programs in oncology and ophthalmology.